^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Neuroendocrine Tumor
    Drug:Somatuline Depot (lanreotide prolonged-release subcutaneous) (SSTR agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Ipsen Press Release
    Title:

    Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

    Published date:
    07/03/2017
    Excerpt:
    Ipsen (Euronext: IPN; ADR: IPSEY) and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, today announced that Teijin Pharma has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen’s subcutaneous drug Somatuline® (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET). 
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Excerpt:
    SOMATULINE DEPOT is a somatostatin analog indicated for:...the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.